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Efforts to reform the U.S. health care system have placed considerable attention on patients’
financial burden from out-of-pocket drug costs. Patients frequently have difficulty paying
for medications and although they are encouraged to discuss ways to lower drug costs with
physicians, such communication frequently fails to occur.1-4 Physicians may be reluctant to
initiate these cost discussions because some cost-cutting strategies involve potential trade-
offs such as increased dosing frequency, or risk of side effects, or lower treatment
effectiveness.1 Knowing patients’ willingness to consider such less than optimal cost-
lowering strategies could encourage physicians to discuss drug costs with their patients.
Corresponding Author (request for reprints): Chien-Wen Tseng, MD MPH Pacific Health Research Institute c/o Univ. of Hawaii
Dept. of Family Medicine and Community Health 677 Ala Moana Blvd, Ste. 815 Honolulu, HI 96813 (808) 692-0852, (808)
627-3262 fax, cwtseng@hawaii.edu.
Financial disclosure : There are no financial conflicts or other author conflicts to disclose.
NIH Public Access
Author Manuscript
Arch Intern Med. Author manuscript; available in PMC 2013 January 29.
Published in final edited form as:
Arch Intern Med. 2010 September 13; 170(16): 1502–1504. doi:10.1001/archinternmed.2010.287.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Methods
We conducted a 2004 patient survey as part of the longitudinal Translating Research Into
Action for Diabetes study to examine diabetes quality of care in 10 health plans and six
states.5 Participants reported whether they wanted physicians to talk about medications that
cost less but a) had to be taken more often, b) may have a slightly higher chance of side
effects, or c) may not work as well.
Results
Of the 5,085 patients (CASRO response rate 75%), two-thirds were willing to discuss at
least one of the three trade-off strategies. Patients said they wanted to be told about lower
cost drugs with higher chance of side-effects (38%), or lower effectiveness (32%), or higher
dosing frequency (59%). Among the 712 participants (14%) who said they had reduced
medication use because of cost, rates were 47%, 42%, and 82% respectively. Even among
the 4,373 participants who had not reduced medication use because of cost, rates were 37%,
30%, and 56% respectively. Among those open to discussing trade-offs, only 19% said their
physician usually or always discussed drug costs when prescribing. In multivariate analyses,
participants with lower income, higher out-of-pocket drug costs, and poorer health were
significantly more willing to discuss trade-offs (Table 1).
Discussion
This is the first large-scale study to examine the willingness of patients with diabetes to
discuss specific types of trade-offs to lower drug costs with their physicians. The majority
wanted physicians to discuss ways to lower drug costs even if it required higher dosing
frequency, and 1 in 3 wanted to know about lower cost drugs with potentially greater side-
effects or lower effectiveness. Importantly, even among participants who did not decrease
medication use because of cost, 1 in 4 wanted to know about cost-lowering strategies that
could negatively affect health. Our findings are novel in that prior studies have only
documented patients’ willingness to discuss out-of-pocket drug costs in general and not
specific strategies that would require trade-offs.3,4 Physicians may be appropriately reluctant
to discuss drug costs when they perceive cost-lowering strategies to be less optimal than
patients’ current medications.1 However, physicians then risk patients reducing medication
use to lower costs without telling their physicians’ or getting their advice.2 The fact that
participants with poor (vs. good) health were significantly more willing to consider such
trade-offs highlights further that physicians need to be actively involved in advising patients
on the appropriateness of such trade-offs. A limitation of our study is that we did not present
specific prescribing scenarios or measure patients’ actual treatment choice. When faced with
real rather than theoretical choices, patients may opt to pay more rather than making any
trade-offs. Patients’ willingness to make tradeoffs may also vary substantially across disease
targets.6 However, our results support that patients are at least open to such discussions with
physicians.
Conclusion
Given patients’ financial burden from drug costs and willingness to discuss drug costs,
physicians should not avoid initiating such cost discussions, even if the available strategies
to lower drug costs could require patients to accept potential trade-offs.
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